In the News
October 22, 2019
Chimeron Bio Announces Appointment of Dr. Robert (Bob) Willette to its Scientific Advisory Board
Chimeron Bio has announced the appointment of Dr. Robert (Bob) Willette to its Scientific Advisory Board.
Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.
Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics to bring more effective gene therapies and personalized medicines to patients.
How we do it
Our ChaESAR Platform
Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.
Why we do it
Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs
We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.
The Latest from Chimeron Bio
From Our Blog
October 22, 2019
Harnessing Ancient Viral Biology to Advance New Age RNA Therapies
RNA, once viewed as passive carriers of genetic information, is arguably the most versatile and potent regulator of biological processes and diseases.
Are you passionate about science and making an impact?
We’re looking for talented individuals to join our team.